Skye Bioscience (FRA:09R0) Total Stockholders Equity: €-0.43 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R0 Skye Bioscience Inc FRA:09R0
19 GF Score
Price €1.73
! 2 Warning Signs
View Full Analysis

What is Skye Bioscience Total Stockholders Equity?

Skye Bioscience FRA:09R0 +13.40% 19 Total Stockholders Equity is €-0.43 Mil as of Jun. 2026. GuruFocus rates FRA:09R0 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Skye Bioscience's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €-0.43 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Skye Bioscience's Book Value per Share for the quarter that ended in Jun. 2026 was €-0.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Skye Bioscience's Debt-to-Equity for the quarter that ended in Jun. 2026 was -0.36.

Skye Bioscience  (FRA:09R0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Skye Bioscience's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-0.431-0)/4.393
=-0.10

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Skye Bioscience's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.155 + 0) / -0.431
=-0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Total Stockholders Equity Related Terms

Skye Bioscience Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Total Stockholders Equity Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.19 -2.84 -1.96 65.09 17.10

Skye Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.87 27.98 17.10 7.80 -0.43
FRA:09R0
19GF Score
Skye Bioscience Inc FRA:09R0
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €-0.43 Mil mean?
Skye Bioscience (FRA:09R0) has a Total Stockholders Equity of €-0.43 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Skye Bioscience and its competitors.
Is Skye Bioscience's Total Stockholders Equity too high?
Skye Bioscience's current Total Stockholders Equity is €-0.43 Mil. Overall, Skye Bioscience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Total Stockholders Equity compare to ATOS and JSPR?
Skye Bioscience's Total Stockholders Equity of €-0.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Skye Bioscience and its competitors. Skye Bioscience's current Total Stockholders Equity is €-0.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R0) has a current Total Stockholders Equity of €-0.43 Mil. The current Total Stockholders Equity is €-0.43 Mil. Skye Bioscience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Skye Bioscience (FRA:09R0), the current Total Stockholders Equity is €-0.43 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
19GF Score

Get the complete analysis for FRA:09R0

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.73
Price